1476776-76-7 Usage
Uses
Used in Pharmaceutical Industry:
N-tert-butyl-1H-indazole-7-carboxamide is used as a pharmaceutical candidate for its potential pharmacological properties. Its indazole structure and the presence of a tert-butyl group contribute to its unique chemical and biological characteristics, making it a promising compound for the development of new drugs and pharmaceutical compounds.
Used in Medicinal Chemistry Research:
N-tert-butyl-1H-indazole-7-carboxamide is used as a research compound in medicinal chemistry. Its unique structure and properties allow scientists to explore its potential interactions with biological targets, such as enzymes, receptors, or other proteins, which could lead to the discovery of new therapeutic agents.
Used in Drug Design and Development:
N-tert-butyl-1H-indazole-7-carboxamide is used as a starting point for drug design and development. Its indazole core and the presence of a tert-butyl group provide opportunities for chemical modifications and optimization to enhance its pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Materials Science and Organic Synthesis:
N-tert-butyl-1H-indazole-7-carboxamide may have potential applications in materials science and organic synthesis due to its unique chemical structure. Its indazole core and the presence of a tert-butyl group could be exploited in the development of new materials with specific properties or as intermediates in the synthesis of other organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1476776-76-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,7,6,7,7 and 6 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1476776-76:
(9*1)+(8*4)+(7*7)+(6*6)+(5*7)+(4*7)+(3*6)+(2*7)+(1*6)=227
227 % 10 = 7
So 1476776-76-7 is a valid CAS Registry Number.
1476776-76-7Relevant academic research and scientific papers
Process development of C-N cross-coupling and enantioselective biocatalytic reactions for the asymmetric synthesis of niraparib
Chung, Cheol K.,Bulger, Paul G.,Kosjek, Birgit,Belyk, Kevin M.,Rivera, Nelo,Scott, Mark E.,Humphrey, Guy R.,Limanto, John,Bachert, Donald C.,Emerson, Khateeta M.
, p. 215 - 227 (2014/05/20)
Process development of the synthesis of the orally active poly(ADP-ribose)polymerase inhibitor niraparib is described. Two new asymmetric routes are reported, which converge on a high-yielding, regioselective, copper-catalyzed Narylation of an indazole derivative as the late-stage fragment coupling step. Novel transaminase-mediated dynamic kinetic resolutions of racemic aldehyde surrogates provided enantioselective syntheses of the 3-aryl-piperidine coupling partner. Conversion of the C-N cross-coupling product to the final API was achieved by deprotection and salt metathesis to isolate the desired crystalline salt form.
